UFIS-SWE-IG
0.1.0 - ci-build
UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions
Full name: Xyloproct Rektalsalva
- Invented Name Part: Xyloproct
- Pharmaceutical dose form part: Rektalsalva
Name usage: Swedish (Kingdom of Sweden)
Authorised dose form: Rectal ointment
Legal status of supply: Medicinal product not subject to medical prescription
Domain: Human use
Resource status: Current
Product classification:
Marketing Authorisation 1 of 1
Authorisation number: 8340
Region: Kingdom of Sweden
Marketing authorisation holder: Aspen Pharma Trading Limited
Identifier:
Status: Valid (1969-01-24)
Package 1 of 1
PCID:
Description: Tub, 20 g
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 1 Tube (Tube)
Containing: 20 gram(s)
Manufactured Item
Dose form: Rectal Ointment
Unit of presentation: Tube
Ingredient
Role: Active
Substance: Lidocaine
Concentration strength: 50 milligram(s) / 1 gram(s)
Reference strength: Lidocaine 50 milligram(s) / 1 gram(s)
Ingredient
Role: Active
Substance: Hydrocortisone acetate
Concentration strength: 2.5 milligram(s) / 1 gram(s)
Reference strength: Hydrocortisone 2.24 milligram(s) / 1 gram(s)
Administrable Product (1 of 1)
Dose form: Rectal Ointment
Unit of presentation:
Route of administration:
Ingredient
Role: Active
Substance: Lidocaine
Concentration strength: 50 milligram(s) / 1 gram(s)
Reference strength: Lidocaine 50 milligram(s) / 1 gram(s)
Ingredient
Role: Active
Substance: Hydrocortisone acetate
Concentration strength: 2.5 milligram(s) / 1 gram(s)
Reference strength: Hydrocortisone 2.24 milligram(s) / 1 gram(s)